SCHEMBL5162771

SCHEMBL5162771

CCOC(=O)CC(=O)c1cc[nH]c1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.49
KMT2A Q03164 2/20 0.49
KDM4E B2RXH2 1/20 0.49
MEN1 O00255 1/20 0.49
GAA P10253 3/20 0.45
TSHR P16473 1/20 0.45
MGAM O43451 1/20 0.45
SI P14410 1/20 0.45
MGAM2 Q2M2H8 1/20 0.45
MAPT P10636 4/20 0.41
PKM P14618 2/20 0.40
HPGD P15428 1/20 0.38
ACACB O00763 1/20 0.38
HSD17B10 Q99714 1/20 0.38
L3MBTL1 Q9Y468 1/20 0.37
MIF P14174 1/20 0.37
LMNA P02545 2/20 0.37
TDP1 Q9NUW8 1/20 0.37
SMN1; SMN2 Q16637 2/20 0.36
NPC1 O15118 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5158168 0.84 KMT2A (0.44) ALDH1A1KMT2AKDM4EMEN1GAA
SCHEMBL671053 0.79 CA12 (0.53) ALDH1A1KMT2AKDM4EMEN1GAA
SCHEMBL5159969 0.79 TSHR (0.40) ALDH1A1KMT2AMEN1TSHRMAPT
Hydrochloric Acid SCHEMBL27813064 0.77 CA12 (0.52) ALDH1A1KMT2AKDM4EMEN1GAA
SCHEMBL5158161 0.77 TSHR (0.51) ALDH1A1TSHRHSD17B10L3MBTL1LMNA
SCHEMBL12638827 0.76
SCHEMBL572 0.75 KMT2A (0.58) ALDH1A1KMT2AKDM4EMEN1GAA
SCHEMBL124577 0.75 KMT2A (0.59) ALDH1A1KMT2AKDM4EMEN1GAA
SCHEMBL17433641 0.74 KMT2A (0.57) ALDH1A1KMT2AKDM4EMEN1GAA
SCHEMBL17433663 0.74 KMT2A (0.57) ALDH1A1KMT2AKDM4EMEN1GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8293899-B2 Ketone transfer hydrogenation of stereoisomerically enriched 3-heteroaryl-3-oxocarboxylic esters by reducing 3-heteroaryl-3-hydroxycarboxylic esters in the presence of a ruthenium-containing catalyst, an amine and formic acid and/or formates LANXESS DEUTSCHLAND GMBH (DE) 2012-10-23 US disclosed
EP-1340746-B1 Process for the reduction of 3-heteroaryl-3-oxo-propanoic acid derivatives SALTIGO GMBH (DE) 2007-02-28 EP disclosed
US-20030225274-A1 Process for reducing 3-heteroaryl-3-oxopropionic acid derivatives LANXESS DEUTSCHLAND GMBH (DE) 2003-12-04 US disclosed
EP-1340746-A1 Process for the reduction of 3-heteroaryl-3-oxo-propanoic acid derivatives BAYER AG (DE) 2003-09-03 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030225274-A1 Process for reducing 3-heteroaryl-3-oxopropionic acid derivatives GRHPR, HPD, HAAO ALDH1A1 273/4885KMT2A 1666/4885KDM4E 862/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.